Zum Inhalt springen

BioWorld: Atriva taking host-targeted antiviral approach into basket study

  • 1 min read

11.11.2022 by Jennifer Boggs – Read the article here

Atriva Therapeutics GmbH, a small firm founded in 2015 to develop a host-targeted antiviral approach for treating respiratory viral infections, seems to have found itself in thick of it. As the U.S. CDC and other health agencies warn of an uptick in respiratory viral infections – the so-called “tripledemic” of influenza, respiratory syncytial virus and COVID-19 – the German company is gearing up to launch a basket trial testing lead candidate zapnometinib in all three indications.